Home Supplements That Start With I Iodixanol: When to Choose It, Imaging Uses, Recommended Dosage, and Side Effects

Iodixanol: When to Choose It, Imaging Uses, Recommended Dosage, and Side Effects

4

Iodixanol is an iso-osmolar, nonionic, dimeric iodinated contrast agent used to enhance blood vessels and organs on X-ray–based imaging such as CT and angiography. “Iso-osmolar” means its osmolality is similar to human plasma, a property designed to improve patient comfort and reduce certain physiologic shifts compared with older, high-osmolar agents. Iodixanol is supplied in two strengths (270 and 320 mg iodine/mL) as a ready-to-use sterile solution for intravascular and intrathecal applications where approved. Clinicians value it for predictable image quality across CT, CTA, and catheter-based procedures, including coronary, peripheral, and neurovascular angiography. Like all iodinated media, safe use hinges on patient selection, dose planning, hydration, and preparation for rare allergic-like reactions. This guide explains how iodixanol works, when to choose it, practical dosing by indication, ways to reduce kidney and thyroid risks, and what to watch for before and after injection.

Essential Insights

  • Iso-osmolar nonionic contrast with plasma-like osmolality (about 290 mOsm/kg) designed for comfortable intravascular injection.
  • Typical adult IV doses for contrast-enhanced CT are procedure-based (often 1.0–1.5 mL/kg; institutional ranges apply); arterial angiography uses tailored volumes per vascular bed.
  • Hydration, risk stratification, and modern protocols reduce contrast-associated acute kidney injury; intranasal oxygen and warm contrast improve tolerance.
  • Avoid routine use in uncontrolled hyperthyroidism; use caution in pregnancy, neonates, and patients with prior severe contrast reactions.

Table of Contents

What iodixanol is and how it works

Chemical class and properties. Iodixanol is a nonionic, dimeric, water-soluble radiographic contrast agent. Each molecule carries six iodine atoms bound in an organic framework that is highly hydrophilic yet electrically neutral. Formulations at 270 mg I/mL and 320 mg I/mL are isotonic with plasma (osmolality about 290 mOsm/kg water), with pH near physiologic range. Because it is iso-osmolar, iodixanol does not draw fluid across vascular membranes to the same extent as older, hyperosmolar agents, a factor linked to improved injection comfort and reduced transient hemodynamic shifts during bolus delivery.

Pharmacokinetics. After intravascular administration, iodixanol remains extracellular. It does not meaningfully bind serum proteins, distributes in plasma and interstitial fluid, and is eliminated largely unchanged by glomerular filtration. In adults with normal kidney function, the terminal half-life is on the order of hours, and most of the dose appears in urine within the first 24 hours. In renal impairment, exposure (AUC) increases and clearance slows proportionally to the fall in eGFR; hemodialysis can remove iodinated contrast if clinically indicated.

Imaging mechanism. The tightly bound iodine atoms attenuate X-rays. By injecting iodixanol as a bolus or controlled infusion, vascular and tissue enhancement peaks during specific time windows—arterial, portal venous, or delayed phases—allowing characterization of stenoses, aneurysms, thrombi, tumors, inflammation, and organ perfusion.

Formulation considerations. Viscosity rises with iodine concentration and falls when the solution is warmed to 37 °C. Warming reduces injection pressures, improves bolus shape for CTA, and can reduce patient discomfort—especially through small-gauge cannulas. The choice between 270 and 320 mg I/mL balances viscosity, iodine delivery per mL, and scanner protocol.

Regulatory status and presentations. Iodixanol is marketed under trade names such as VISIPAQUE in single-dose vials or bottles without preservatives. Because it is a prescription drug, storage, warming, and handling follow labeled instructions and facility policy. Opened containers are single-use for one patient and procedure.

Back to top ↑

When to choose iodixanol

Typical use cases.

  • CT and CTA: Routine thoracic, abdominal, and pelvic contrast-enhanced CT; coronary and peripheral CT angiography benefit from consistent, high-iodine boluses.
  • Catheter angiography: Coronary, neurovascular, peripheral, and visceral angiograms; endovascular treatments (stent, coil, embolization) where repeated injections occur.
  • Pediatric and fragile patients: Iso-osmolarity and careful dosing protocols can improve tolerability, particularly when small IV catheters or high-rate injections are necessary.

When iso-osmolarity adds value.

  • High-rate boluses for CTA (e.g., coronary) where injection comfort and hemodynamic stability matter.
  • Patients with borderline hemodynamics who may be sensitive to fluid shifts.
  • History of discomfort with prior contrast where a change in osmolality and warming can improve tolerance.

Kidney risk perspective. The modern view distinguishes contrast-associated AKI (temporal association) from contrast-induced AKI (causal). With current hydration practices and better risk stratification, the absolute risk attributable to contemporary iodinated agents is lower than historically believed—especially for eGFR ≥30 mL/min/1.73 m² in the absence of acute kidney injury. Studies comparing iso-osmolar iodixanol with low-osmolar agents show comparable renal outcomes in most IV CT settings; in selected intra-arterial procedures with renal impairment, some analyses show fewer creatinine rises with iodixanol versus specific comparators (not all).

Allergic-like reaction history. For a patient with a prior severe allergic-like reaction to iodinated contrast, any iodinated agent—including iodixanol—is a relative contraindication. If contrast is essential, premedication and an alternative agent may be considered after risk–benefit review. For mild prior reactions, strategies include premedication, switching to a different agent class, and careful monitoring.

Thyroid considerations. Iodine load can transiently alter thyroid function. Avoid elective high-iodine exposure in uncontrolled hyperthyroidism. In pregnancy, use only when imaging benefit clearly outweighs risk; fetal thyroid uptake begins in the second trimester, and neonatal TSH screening is recommended after significant in-utero exposure. In neonates and infants, even small iodine loads can disturb thyroid function—dose conservatively and follow local pediatric guidance.

When another agent may be preferable.

  • Very high-speed injections via tiny catheters where a lower-viscosity, low-osmolar agent could reach target flow more reliably.
  • Intrathecal myelography if a specific low-osmolar brand is the only approved formulation locally for that route (always follow labeling).
  • Institution-standardized CT protocols optimized around another agent’s viscosity/iodine curve; consistency across scanners matters for image quality and dose tracking.

Back to top ↑

How to dose by study type

General principles. Dose planning aims to deliver adequate total iodine to the target circulation during the desired scan phase while minimizing volume. Protocols differ by scanner, patient size, and indication. Many centers target 1.0–1.5 mL/kg for routine adult IV contrast-enhanced CT, adjusting for concentration, flow rate, and timing. Maximum cumulative dose limits are typically set by institutional policy (for example, ≤4 mL/kg total on a given day), with lower limits for vulnerable patients.

Common adult IV CT ranges (illustrative; follow local policy):

  • CT chest/abdomen/pelvis: 80–120 mL at 320 mg I/mL (or 100–150 mL at 270 mg I/mL), injected at 2–4 mL/s.
  • Liver multiphase: 90–120 mL at 3–5 mL/s, with arterial and portal venous acquisitions timed by bolus tracking.
  • CT pulmonary angiography: 60–80 mL at 4–6 mL/s, saline chaser 30–50 mL to sharpen the bolus.
  • Coronary CTA: 50–80 mL at 4–6 mL/s, individualized to BMI and scanner speed; always include a saline chaser.

Catheter angiography (arterial intra-arterial injections):

  • Coronary diagnostic angiography: Multiple small boluses, often 3–8 mL per shot (right/left), tailored to catheter size and frame rate.
  • Neuroangiography: Selective injections 4–10 mL per vessel; careful attention to osmolality, viscosity, and catheter diameter.
  • Peripheral/visceral: Variable boluses 5–20 mL, repeated as needed for road-mapping and treatment checks.
    Cumulative volume should be tracked throughout the case, especially in renal impairment.

Pediatrics. Dosing is by weight and indication, frequently 1.5–2.0 mL/kg IV for many CT protocols, capped to a maximum volume defined by the service line. Smaller cannulas mandate warming to 37 °C and thoughtful flow-rate limits to prevent extravasation. Pediatric sedation and monitoring policies apply.

Intrathecal (if locally approved). Only use formulations labeled for intrathecal injection, at the exact concentration, volume, and rate specified; never substitute concentrations or mix with other drugs. Aspiration/re-injection techniques and post-procedure head elevation reduce adverse events.

Practical bolus optimization.

  • Warm the contrast to 37 °C to reduce viscosity and allow smooth high-rate injections.
  • Use a saline chaser to reduce streak artifact and contrast pooling in the arm.
  • Right-sided IV is preferred for chest CTA to reduce streak from the left innominate vein.
  • Pressure limits must match catheter gauge and site; always observe for pain or swelling signaling extravasation.

Documentation to include. Agent name and concentration, total volume, injection site, gauge, flow rate, use of test bolus or bolus tracking, and immediate patient response. Record lot and expiration per medication policy.

Back to top ↑

How to reduce risks and improve safety

Screen smart—not everyone needs labs. For stable outpatients with eGFR ≥30, routine creatinine checks on the day of CT are often unnecessary unless risk factors or acute illness are present. Screen for recent AKI, advanced CKD, kidney transplant, dialysis, solitary kidney with poor function, or planned high-volume intra-arterial studies.

Hydration remains the cornerstone. For higher-risk patients (e.g., eGFR <30, recent AKI, large intra-arterial dose), isotonic saline protocols before and after contrast lower CA-AKI risk. Typical examples include 1 mL/kg/h beginning several hours prior and continuing 6–12 hours after, with individualized rates for heart failure. Oral hydration helps but is less predictable in high-risk scenarios.

Metformin handling. Patients with eGFR ≥30 and no evidence of AKI generally do not need to stop metformin for IV iodinated contrast. If eGFR <30 or AKI is present, withhold metformin at or before the exam and reassess renal function 48 hours later before resumption.

Premedication for prior allergic-like reactions. When a patient has a moderate or severe prior reaction and contrast is essential, commonly used regimens include:

  • Prednisone 50 mg orally at 13, 7, and 1 hour before injection plus diphenhydramine 50 mg 1 hour before; or
  • Methylprednisolone 32 mg orally at 12 and 2 hours before injection; H1/H2 blockers per protocol.
    Accelerated regimens are less effective; use only when delays are impossible and benefits clearly outweigh risks. Always have resuscitation-ready staff and equipment on site.

Anaphylaxis preparedness. Stock weight-based epinephrine, airway supplies, IV fluids, and adjuncts (albuterol, antihistamines, steroids). Train staff with mock codes. Record the event thoroughly and refer patients for allergy consultation.

Extravasation prevention and management. Use intact veins with appropriate catheter gauge; verify patency by saline test. If extravasation occurs: stop injection, elevate limb, apply cool or warm compress per institutional preference, and assess volume and symptoms. Surgical consultation is prudent for large-volume or compartment syndrome signs.

Thyroid monitoring. Avoid elective iodinated contrast in overt hyperthyroidism. In neonates exposed in utero or postnatally, ensure newborn TSH screening proceeds as scheduled; consider additional thyroid testing if clinically indicated. In thyroid cancer patients receiving radioiodine therapy, contrast may delay uptake by saturating iodine stores; coordinate timing with the oncology team.

Dialysis patients. Iodinated contrast can be given when clinically needed; an extra dialysis session is generally not required solely to remove contrast, but schedule imaging to align with routine dialysis if convenient.

Communication and checklists. Verify allergies, kidney and thyroid history, medications, pregnancy status, and access plan. Standardized contrast checklists reduce omissions and improve safety across teams.

Back to top ↑

Side effects and who should avoid

Common and usually mild effects.

  • Warmth or flushing along the injection limb and chest; a metallic taste.
  • Nausea or transient vomiting, more likely with rapid injections or anxiety.
  • Injection-site discomfort or minor bruising.

Allergic-like and physiologic reactions.

  • Allergic-like: Urticaria, pruritus, angioedema, bronchospasm, or anaphylaxis; risk is higher with a prior reaction to iodinated contrast.
  • Physiologic: Vasovagal responses, transient hypotension, or arrhythmias—generally self-limited with observation and supportive care.

Kidney effects.

  • In contemporary practice with hydration and evidence-based selection, contrast-associated AKI after IV CT is uncommon in patients with eGFR ≥30. Risk rises with lower eGFR, intra-arterial first-pass renal exposure, hemodynamic instability, large cumulative volumes, and concomitant nephrotoxins. For these patients, minimize dose, optimize hemodynamics, and hydrate.

Thyroid effects.

  • Hyperthyroidism exacerbation is possible in susceptible patients; defer nonurgent contrast until stabilized.
  • Neonatal hypothyroidism can occur after in-utero or early-life exposure; ensure routine newborn screening and extra testing if clinically warranted.
  • Thyroid cancer care may be impacted due to iodine load interfering with upcoming radioiodine therapy.

Who should avoid or defer iodixanol without specialist input.

  • Active, uncontrolled hyperthyroidism or thyroid storm.
  • Severe, uncontrolled asthma with recent exacerbations and prior contrast anaphylaxis despite premedication.
  • eGFR <30 with ongoing AKI when imaging can reasonably wait for stabilization or alternative modalities (e.g., ultrasound, noncontrast CT, MRI without iodinated contrast).
  • Pregnancy when diagnostic alternatives provide adequate answers without iodinated exposure; if contrast is necessary, use the lowest effective dose, document rationale, and inform obstetric care.

Drug and substance interactions.

  • Metformin: management as above.
  • Nephrotoxins (e.g., high-dose NSAIDs, calcineurin inhibitors): consider temporary adjustment and hydration.
  • Radioiodine therapy: delay after contrast until iodine stores normalize per oncology/endocrine plan.

Patient counseling points. Most reactions occur within minutes. Delayed rashes can appear within hours to days; advise patients to seek care for breathing difficulty, swelling, rash, fever, reduced urine output, or uncontrolled pain/swelling at the injection site. Provide written instructions and emergency contacts after high-risk procedures.

Back to top ↑

Evidence: numbers that matter

  • Osmolality: Iodixanol solutions are ~290 mOsm/kg water (iso-osmolar to plasma).
  • Concentrations: 270 and 320 mg iodine/mL in single-dose vials/bottles; warmed to 37 °C before high-rate injection to reduce viscosity.
  • Distribution and elimination: Extracellular distribution; renal excretion of unchanged drug is the dominant pathway; dialyzable.
  • Kidney risk comparisons: Across most IV CT contexts, iso-osmolar iodixanol and low-osmolar agents show similar CI-AKI rates when modern hydration protocols are used. Selected intra-arterial studies in high-risk patients show fewer creatinine rises with iodixanol compared to specific comparators (not universal across all low-osmolar agents).
  • Premedication timing that works: Corticosteroid regimens starting ≥12–13 hours before injection show the best prevention for allergic-like reactions in patients with prior moderate/severe reactions; “rapid” 1–2-hour regimens are less reliable and reserved for urgent needs.
  • Metformin: With eGFR ≥30 and no AKI, routine holding is not necessary for IV studies; if eGFR <30 or AKI, hold and reassess at 48 hours.
  • Neonates and pregnancy: Iodine load can alter neonatal thyroid function; ensure routine screening and test if clinically indicated after significant exposure.

At-a-glance protocol ideas for teams (adapt locally):

  1. Risk screen: eGFR, AKI, prior reaction, thyroid status, pregnancy, medications.
  2. Hydrate: Saline for high-risk; encourage oral fluids for low-risk.
  3. Warm contrast: 37 °C; use saline chaser.
  4. Dose: Target iodine delivery for indication; watch cumulative volume.
  5. Monitor: Observe ≥15 minutes post-injection in higher-risk patients; provide delayed reaction guidance.
  6. Document: Agent, lot, volume, flow, site, and outcomes; update allergy lists accurately (allergic-like vs physiologic).

Back to top ↑

References

Medical Disclaimer

This article provides general information for patients and clinicians and is not a substitute for personalized medical advice, diagnosis, or treatment. Dosing, screening, and risk-reduction strategies for iodinated contrast—including iodixanol—should follow local protocols and clinician judgment based on the patient’s condition. If you have kidney disease, thyroid disorders, are pregnant, or have had a prior contrast reaction, discuss risks and alternatives with your care team before imaging. If this guide was helpful, please consider sharing it on Facebook, X (formerly Twitter), or another platform you prefer, and follow us on social media; your support helps us continue creating clear, evidence-informed health content.

RELATED ARTICLESMORE FROM AUTHOR